Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 35

1.

Avatrombopag, an Alternate Treatment Option to Reduce Platelet Transfusions in Patients with Thrombocytopenia and Chronic Liver Disease-Integrated Analyses of 2 Phase 3 Studies.

Poordad F, Terrault NA, Alkhouri N, Tian W, Allen LF, Rabinovitz M.

Int J Hepatol. 2020 Jan 25;2020:5421632. doi: 10.1155/2020/5421632. eCollection 2020.

2.

Avatrombopag, an oral thrombopoietin receptor agonist: results of two double-blind, dose-rising, placebo-controlled Phase 1 studies.

Kuter DJ, Allen LF.

Br J Haematol. 2018 Nov;183(3):466-478. doi: 10.1111/bjh.15574. Epub 2018 Sep 11.

3.

Phase 3 randomised study of avatrombopag, a novel thrombopoietin receptor agonist for the treatment of chronic immune thrombocytopenia.

Jurczak W, Chojnowski K, Mayer J, Krawczyk K, Jamieson BD, Tian W, Allen LF.

Br J Haematol. 2018 Nov;183(3):479-490. doi: 10.1111/bjh.15573. Epub 2018 Sep 7.

4.

Avatrombopag Before Procedures Reduces Need for Platelet Transfusion in Patients With Chronic Liver Disease and Thrombocytopenia.

Terrault N, Chen YC, Izumi N, Kayali Z, Mitrut P, Tak WY, Allen LF, Hassanein T.

Gastroenterology. 2018 Sep;155(3):705-718. doi: 10.1053/j.gastro.2018.05.025. Epub 2018 May 17.

5.

Ferumoxytol versus placebo in iron deficiency anemia: efficacy, safety, and quality of life in patients with gastrointestinal disorders.

Ford DC, Dahl NV, Strauss WE, Barish CF, Hetzel DJ, Bernard K, Li Z, Allen LF.

Clin Exp Gastroenterol. 2016 Jul 11;9:151-62. doi: 10.2147/CEG.S101473. eCollection 2016.

6.

Ferumoxytol versus iron sucrose treatment: a post-hoc analysis of randomized controlled trials in patients with varying renal function and iron deficiency anemia.

Strauss WE, Dahl NV, Li Z, Lau G, Allen LF.

BMC Hematol. 2016 Jul 26;16:20. doi: 10.1186/s12878-016-0060-x. eCollection 2016.

7.

Pharmacokinetics, metabolism, and excretion of (14)C-labeled belinostat in patients with recurrent or progressive malignancies.

Calvo E, Reddy G, Boni V, García-Cañamaque L, Song T, Tjornelund J, Choi MR, Allen LF.

Invest New Drugs. 2016 Apr;34(2):193-201. doi: 10.1007/s10637-015-0321-8. Epub 2016 Jan 14.

PMID:
26769244
8.

Safety and efficacy of ferumoxytol for the episodic treatment of iron deficiency anemia in patients with a history of unsatisfactory oral iron therapy: Results of a phase III, open-label, 6-month extension study.

Vadhan-Raj S, Ford DC, Dahl NV, Bernard K, Li Z, Allen LF, Strauss WE.

Am J Hematol. 2016 Feb;91(2):E3-5. doi: 10.1002/ajh.24240. No abstract available.

9.

A Phase IIb, Multicenter, Open-Label, Safety, and Efficacy Study of High-Dose, Propylene Glycol-Free Melphalan Hydrochloride for Injection (EVOMELA) for Myeloablative Conditioning in Multiple Myeloma Patients Undergoing Autologous Transplantation.

Hari P, Aljitawi OS, Arce-Lara C, Nath R, Callander N, Bhat G, Allen LF, Stockerl-Goldstein K.

Biol Blood Marrow Transplant. 2015 Dec;21(12):2100-2105. doi: 10.1016/j.bbmt.2015.08.026. Epub 2015 Aug 29.

10.

Belinostat in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma: Results of the Pivotal Phase II BELIEF (CLN-19) Study.

O'Connor OA, Horwitz S, Masszi T, Van Hoof A, Brown P, Doorduijn J, Hess G, Jurczak W, Knoblauch P, Chawla S, Bhat G, Choi MR, Walewski J, Savage K, Foss F, Allen LF, Shustov A.

J Clin Oncol. 2015 Aug 10;33(23):2492-9. doi: 10.1200/JCO.2014.59.2782. Epub 2015 Jun 22.

11.

Qualitative and quantitative validation of the FACIT-fatigue scale in iron deficiency anemia.

Acaster S, Dickerhoof R, DeBusk K, Bernard K, Strauss W, Allen LF.

Health Qual Life Outcomes. 2015 May 17;13:60. doi: 10.1186/s12955-015-0257-x.

12.

A Phase II trial of Belinostat (PXD101) in patients with relapsed or refractory peripheral or cutaneous T-cell lymphoma.

Foss F, Advani R, Duvic M, Hymes KB, Intragumtornchai T, Lekhakula A, Shpilberg O, Lerner A, Belt RJ, Jacobsen ED, Laurent G, Ben-Yehuda D, Beylot-Barry M, Hillen U, Knoblauch P, Bhat G, Chawla S, Allen LF, Pohlman B.

Br J Haematol. 2015 Mar;168(6):811-9. doi: 10.1111/bjh.13222. Epub 2014 Nov 17.

PMID:
25404094
13.
14.

Efficacy and safety of IV ferumoxytol for adults with iron deficiency anemia previously unresponsive to or unable to tolerate oral iron.

Vadhan-Raj S, Strauss W, Ford D, Bernard K, Boccia R, Li J, Allen LF.

Am J Hematol. 2014 Jan;89(1):7-12. doi: 10.1002/ajh.23582. Epub 2013 Sep 30.

15.

CI-1040 (PD184352), a targeted signal transduction inhibitor of MEK (MAPKK).

Allen LF, Sebolt-Leopold J, Meyer MB.

Semin Oncol. 2003 Oct;30(5 Suppl 16):105-16. Review.

PMID:
14613031
16.

CI-1033, an irreversible pan-erbB receptor inhibitor and its potential application for the treatment of breast cancer.

Allen LF, Eiseman IA, Fry DW, Lenehan PF.

Semin Oncol. 2003 Oct;30(5 Suppl 16):65-78. Review.

PMID:
14613028
17.

Potential benefits of the irreversible pan-erbB inhibitor, CI-1033, in the treatment of breast cancer.

Allen LF, Lenehan PF, Eiseman IA, Elliott WL, Fry DW.

Semin Oncol. 2002 Jun;29(3 Suppl 11):11-21. Review.

PMID:
12138393
18.

Phase I and pharmacokinetic study of LU79553, a DNA intercalating bisnaphthalimide, in patients with solid malignancies.

Villalona-Calero MA, Eder JP, Toppmeyer DL, Allen LF, Fram R, Velagapudi R, Myers M, Amato A, Kagen-Hallet K, Razvillas B, Kufe DW, Von Hoff DD, Rowinsky EK.

J Clin Oncol. 2001 Feb 1;19(3):857-69.

PMID:
11157040
19.

A phase I clinical and pharmacokinetic study of the dolastatin analogue cemadotin administered as a 5-day continuous intravenous infusion.

Supko JG, Lynch TJ, Clark JW, Fram R, Allen LF, Velagapudi R, Kufe DW, Eder JP Jr.

Cancer Chemother Pharmacol. 2000;46(4):319-28.

PMID:
11052630
20.
23.

Physiological effects of inverse agonists in transgenic mice with myocardial overexpression of the beta 2-adrenoceptor.

Bond RA, Leff P, Johnson TD, Milano CA, Rockman HA, McMinn TR, Apparsundaram S, Hyek MF, Kenakin TP, Allen LF, et al.

Nature. 1995 Mar 16;374(6519):272-6.

PMID:
7885448
24.

Marked enhancement in myocardial function resulting from overexpression of a human beta-adrenergic receptor gene.

Milano CA, Allen LF, Dolber PC, Johnson TD, Rockman HA, Bond RA, Lefkowitz RJ.

J Thorac Cardiovasc Surg. 1995 Feb;109(2):236-41.

26.
27.

Myocardial expression of a constitutively active alpha 1B-adrenergic receptor in transgenic mice induces cardiac hypertrophy.

Milano CA, Dolber PC, Rockman HA, Bond RA, Venable ME, Allen LF, Lefkowitz RJ.

Proc Natl Acad Sci U S A. 1994 Oct 11;91(21):10109-13.

28.

Enhanced myocardial function in transgenic mice overexpressing the beta 2-adrenergic receptor.

Milano CA, Allen LF, Rockman HA, Dolber PC, McMinn TR, Chien KR, Johnson TD, Bond RA, Lefkowitz RJ.

Science. 1994 Apr 22;264(5158):582-6.

PMID:
8160017
29.
30.

Identification, quantification, and localization of mRNA for three distinct alpha 1 adrenergic receptor subtypes in human prostate.

Price DT, Schwinn DA, Lomasney JW, Allen LF, Caron MG, Lefkowitz RJ.

J Urol. 1993 Aug;150(2 Pt 1):546-51.

PMID:
7686987
31.

Phase I trial of iodine-131-chimeric B72.3 (human IgG4) in metastatic colorectal cancer.

Meredith RF, Khazaeli MB, Plott WE, Saleh MN, Liu T, Allen LF, Russell CD, Orr RA, Colcher D, Schlom J, et al.

J Nucl Med. 1992 Jan;33(1):23-9.

32.
33.

The effects of intrauterine cocaine exposure: transient or teratogenic?

Allen LF, Palomares RS, DeForest P, Sprinkle B, Reynolds CR.

Arch Clin Neuropsychol. 1991;6(3):133-46.

PMID:
14591861
34.

Expansion of the alpha 2-adrenergic receptor family: cloning and characterization of a human alpha 2-adrenergic receptor subtype, the gene for which is located on chromosome 2.

Lomasney JW, Lorenz W, Allen LF, King K, Regan JW, Yang-Feng TL, Caron MG, Lefkowitz RJ.

Proc Natl Acad Sci U S A. 1990 Jul;87(13):5094-8.

35.

Acarapis mites on honeybees.

de Chaneet G, Kessell AC, Allen LF.

Aust Vet J. 1984 Oct;61(10):322-3. No abstract available.

PMID:
6525117

Supplemental Content

Loading ...
Support Center